Friday, 18 Jan 2019


Wine (and Food) and the Rheumatologist Attends EULAR 2016

After several months’ hiatus, I am back and writing about my recent trip to London. My past blogs centered on wine from my rheumatology-related trips and experiences. Moving forward I'm adding a culinary dimension; hence, it will be Wine, Food and the Rheumatologist. My bone fides? Well, I like to eat, that is for sure - but more than that, I like to cook. 

Morning Stiffness Madness

Rheumatologists distinguish themselves from their medical colleagues in several ways: exceptional joint exam and joint injection skills, interpretation of complex immunologic findings and cost-efficient ways of managing common musculoskeletal disorders. But what’s the one trait, skill or question that defines the acumen of the rheumatologist? Please don’t say morning stiffness. 

Listen to the Patient…She’s Telling You the Diagnosis

I had a 20-minute visit scheduled with Mrs. Goldstein yesterday. She is a thin, foreign-born, older woman with rheumatoid arthritis, recently complicated by lymphoma. As I sat, I asked “where is your husband this morning”, as he usually attends her medical visits. I had already turned to the computer and started to bring up her file, meds, etc. There was a long pause before she finally answered.   

Improving Drug Safety Communications

What do you call it when you say one thing and the listener hears something else?

Guiding Patients Considering Biologics

What are the questions patients should ask their doctors about biologics? Are there rules for starting and stopping biologics?

The Errors that Underlie 'Medical Errors' in the News

Upon reading the title of a recent news item - 'Medical error is the third leading cause of death in the US' - a feeling of apprehension and dread arose. Very quickly, my worst fears were realized.

Biologic Prescribing and Patient Education

Biologics are big. Their popularity is reflected in their growing use since being introduced in 1998. Biologics have been used by more than 3 million patients worldwide. In 2013, Enbrel, Remicade and Humira accounted for nearly $30 billion in worldwide sales. In the USA, it is estimated that we will spend $220 billion on biologics by 2017. 

What It’s Like to Work with a KOL (Key Opinion Leader)

Rheumatology is fortunate to have many "key opinion leaders" (KOLs) to teach, study, synthesize and pave the advances in our discipline.  Who are these KOLs and how can we tell them apart? 

Why Not Just Kick the TNFi Habit?

Why do we use TNF inhibitors as our first biologic choice?  Is it the evidence of efficacy, access, safety, and drug retention, or is it a prescriber habit that merits critique?  

RheumNow Anniversary Perspective

Dr. Jack Cush provides a perspective on the first year anniversary of - a site dedicated to delivering the wisdom, art and science of Rheumatology. 

KOLs Predict: What Will the Next Year Bring?

A new subspecialty may emerge. New drugs will be approved (but it will be difficult for patients to get coverage for them). And an American team will win the World Series. All these and more: here are predictions for 2017 and beyond from rheumatologists across the country and around the world.


"A Touch of Humanity": Seven Perspectives on RheumNow

"Making the complex simple, the simple useful, and the opaque crystal clear." Rheumatologists (plus one non-rheumatologist) from around the world weigh in on RheumNow's impact over the past year.